Abstract 5259: Non-invasive determination of in vivo myeloperoxidase activity in ovarian cancer mouse model

Conformal modulus sensors (CMS) incorporate PZT nanoribbons as mechanical actuators and sensors to achieve reversible conformal contact with the human skin for non-invasive, in vivo measurements of skin modulus. An analytic model presented in this paper yields expressions that connect the sensor output voltage to the Young moduli of the epidermis and dermis, the thickness of the epidermis, as well as the material and geometrical parameters of the CMS device itself and its encapsulation layer. Results from the model agree well with in vitro experiments on bilayer structures of poly(dimethylsiloxane). These results provide a means to determine the skin moduli (epidermis and dermis) and the thickness of the epidermis from in vivo measurements of human skin.

Download Full-text

Induced myeloperoxidase activity in ovarian cancer mouse model

The FASEB Journal ◽

10.1096/fasebj.26.1_supplement.657.6 ◽

2012 ◽

Vol 26 (S1) ◽

Author(s):

Rao V Papineni ◽

Gil Mor ◽

William McLaughlin ◽

Jennie Holmberg ◽

Vinicius Craveiro

Keyword(s):

Ovarian Cancer ◽

Mouse Model ◽

Myeloperoxidase Activity

Download Full-text

Factors Affecting the Validity of the 13C-Urea Breath Test for In Vivo Determination of Helicobacter pylori Infection Status in a Mouse Model

Helicobacter ◽

10.1046/j.1523-5378.1999.99283.x ◽

1999 ◽

Vol 4 (4) ◽

pp. 260-265 ◽

Cited By ~ 4

Author(s):

Paul D. Hammond ◽

Fred J. Stutzenberger ◽

Ross N. Butler ◽

Leanna C. Read ◽

Geoffrey P. Davidson

Keyword(s):

Helicobacter Pylori ◽

Mouse Model ◽

Breath Test ◽

Urea Breath Test ◽

Helicobacter Pylori Infection ◽

Infection Status ◽

Factors Affecting ◽

13C Urea Breath Test

Download Full-text

Therapeutic efficacy of an oncolytic adenovirus monitored by in vivo imaging of an ovarian cancer model

Journal of Clinical Oncology ◽

10.1200/jco.2006.24.18_suppl.10061 ◽

2006 ◽

Vol 24 (18_suppl) ◽

pp. 10061-10061

Author(s):

Y. Tsuruta ◽

L. Pereboeva ◽

D. T. Rein ◽

M. Breidenbach ◽

D. T. Curiel

Keyword(s):

Ovarian Cancer ◽

Tumor Growth ◽

Cancer Cells ◽

Murine Model ◽

Ovarian Cancer Cell ◽

Imaging System ◽

Wild Type ◽

Non Invasive ◽

Ovarian Cancer Cell Lines

10061 Background: Although a number of advances in ovarian cancer treatment have occurred in the last decade, most patients will experience a recurrence after standard therapies. Recently, virotherapy has been proposed as a new therapeutic approach for ovarian cancer. Conditionally replicative adenovirus (CRAd) contains tumor-specific promoters that restrict virus replication to cancer cells and has shown particular promise as oncolytic viral agents. However, the lack of a tumor-volume monitoring system hinders the evaluation of CRAd impact on cancer treatment. Therefore, methods for analyzing CRAd efficacy and tumor response are required. Mesothelin, a cell surface glycoprotein, is overexpressed in ovarian cancer but not in normal ovarian tissues. The purpose of this study was to explore the therapeutic utility of a mesothelin promoter-based CRAd in a murine model of ovarian cancer, using a non-invasive biological imaging system. Methods: We constructed a mesothelin promoter based CRAd which also contains a modified fiber (Ad5/3 fiber) previously shown to improve infectivity of many ovarian cancer cells (Ad5/3MSLN). Viral replication and oncolysis were assessed in a panel of ovarian cancer cell lines. To test the oncolytic efficacy of Ad5/3MSLN in murine model, firefly luciferase-expressing SK-OV-3-luc cells were injected intraperitoneally (i.p.), followed by an i.p. injection of viruses. Then, bioluminescence imaging of tumor luciferase activity was carried out. Results: Ad5/3MSLN achieved up to 10,000-fold higher cell killing effect and up to 120-fold higher levels of viral replication in all ovarian cancer cell lines tested, compared to wild type Ad5. In vivo tumor imaging confirmed that Ad5/3MSLN significantly inhibited tumor growth, while the untreated mice had rapid tumor growth (p<0.05). Survival with Ad5/3MSLN was significantly enhanced when compared with no virus, or wild type Ad5-treated group (p<0.05). Conclusions: The robust replication, oncolysis, and in vivo therapeutic efficacy of Ad5/3MSLN demonstrated that this CRAd is a promising candidate for treating ovarian cancer. Importantly, we have established an in vivo non-invasive imaging system, which has allowed repeated and longitudinal measurements of tumor growth after CRAd treatment. No significant financial relationships to disclose.

Download Full-text

Abstract 17280: A New in vivo Imaging Protocol for Non-Invasive Detection of Right Ventricular Dysfunction in a Pulmonary Hypertension Mouse Model

Circulation ◽

10.1161/circ.138.suppl_1.17280 ◽

2018 ◽

Vol 138 (Suppl_1) ◽

Author(s):

Thomas Hansen ◽

Kristen Bubb ◽

Gemma Figtree

Keyword(s):

Pulmonary Hypertension ◽

Mouse Model ◽

Right Ventricular ◽

Systolic Pressure ◽

Saline Control ◽

Novel Therapies ◽

Imaging Protocol ◽

Non Invasive ◽

Rv Function

Introduction: Accurate measurements of right ventricular (RV) function are critical for studying novel therapies impacting the heart and pulmonary circulation. Until now, assessment in mouse models has relied on invasive measures. Improvements in mouse echocardiography may facilitate application of measures recently validated in humans, including tricuspid annular plane systolic excursion (TAPSE) and RV-S’ (systolic excursion velocity), to allow non-invasive assessment of RV function. Aims: To apply and validate TAPSE and RV-S’ using high-resolution echocardiography for the measurement of RV function in a mouse model of pulmonary hypertension (PH). Methods: Echocardiography was performed on mice 3 weeks after induction of PH using inhaled bleomycin or saline control. PAT, TAPSE and RV-S’ were recorded in mice using a 55-mHz transducer (Visualsonics, Vevo3100). Invasive measurements of right ventricular systolic pressure (RVSP) were obtained via catheterisation of the internal jugular vein, prior to culling. Results: RVSP was significantly elevated in bleomycin-treated mice ( 33.41±0.8mmHg n=10) compared to controls ( 25.66±0.9mmHg n=11; p<0.0001). Similarly, RV hypertrophy was observed in bleomycin mice [RV:body weight 1.156±0.03g/kg n=11] compared with control ( 0.968±0.02g/kg n=12; p=0.0002). TAPSE was sensitive to these differences, being significantly reduced in bleomycin mice ( 0.5739±0.020mm n=8) compared with control ( 0.7387±0.033mm n=10; p=0.0012), and correlated significantly with invasive RVSP (r 2 =0.7218; p<0.0001). RV-S’ was also reduced in bleomycin mice (18.14±0.98mm/s n=7) compared with control (25.38±1.24mm/s n=8; p=0.0006) and correlated strongly with RVSP (r 2 =0.6378; p=0.0011). The correlation of both TAPSE and RV-S’ with RVSP compared favourably to the previously used surrogate measure of RVSP in mice, PAT (r 2 =0.5278; p=0.0002). Conclusions: TAPSE and RV-S’ can be applied in mouse echocardiography, and are sensitive, non-invasive measures of PH and RV dysfunction, comparing well with gold-standard invasive right ventricular systolic pressures. This may benefit the power of future preclinical studies of novel therapies in pulmonary hypertension and RV dysfunction.

Download Full-text